Dr. Natasha Shtraizent is the Co-founder and CEO of Frezent Biological Solutions. She has over 12 years of experience in cancer research across academia and industry. She holds a PhD in Developmental and Cell Biology and Biochemistry from Tel Aviv University and Mount Sinai School of Medicine. She also completed postdoctoral fellowships in cancer research at the Research Foundation, CUNY, and the Icahn School of Medicine at Mount Sinai. Dr. Shtraizent’s scientific expertise focuses on metabolic transformation in cancer and oncogenic mutations in the p53 gene. Her research has contributed to the development of therapies targeting drug-resistant cancers. She has published over 20 articles in peer-reviewed journals and co-authored several patent applications. Prior to assuming the role of CEO at Frezent, Dr. Shtraizent served as a senior scientist in translational oncology at Bristol Myers Squibb.